Skip to content
HowShorted

Acrivon Therapeutics, Inc. short interest in 2023

In 2023, Acrivon Therapeutics, Inc.'s disclosed short interest ran from 0.33% of shares outstanding on 13 Jan 2023 to 1.43% on 29 Dec 2023, a change of +1.10 percentage points. The year's high was 1.90% on 31 Mar 2023 and its low 0.31% on 31 Jan 2023, averaging 1.33% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 47.41 days on 29 Sep 2023. Full history: Acrivon Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Acrivon Therapeutics, Inc. in 2023

2023 in figures

Start of year
0.33% (13 Jan 2023)
End of year
1.43% (29 Dec 2023)
Change
+1.10 pp
High
1.90% (31 Mar 2023)
Low
0.31% (31 Jan 2023)
Average
1.33%
Highest days to cover
47.41 (29 Sep 2023)
SEC filings marked
10

Every report in 2023

Acrivon Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20230.33%6.60
31 Jan 20230.31%11.11
15 Feb 20230.32%1.49
28 Feb 20230.48%1.81
15 Mar 20230.93%2.31results (8-K)
31 Mar 20231.90%1.9510-K filed, results (8-K)
14 Apr 20231.87%10.34
28 Apr 20231.88%20.19
15 May 20231.85%15.16results (8-K), 10-Q filed, results (8-K)
31 May 20231.74%17.96
15 Jun 20231.64%13.35
30 Jun 20231.65%6.37
14 Jul 20231.58%29.68
31 Jul 20231.53%19.56
15 Aug 20231.50%25.6610-Q filed, results (8-K)
31 Aug 20231.46%36.30
15 Sep 20231.46%17.52
29 Sep 20231.44%47.41
13 Oct 20231.38%15.12
31 Oct 20231.39%12.83
15 Nov 20231.31%11.3110-Q filed, results (8-K)
30 Nov 20231.28%12.32
15 Dec 20231.32%6.11
29 Dec 20231.43%11.12

See also: Acrivon Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.